Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib


Por: Cebrian A, del Pulgar T, Mendez-Vidal M, Gonzalvez M, Lainez N, Castellano D, Garcia-Carbonero I, Esteban E, Saez M, Villatoro R, Suarez C, Carrato A, Munarriz-Ferrandiz J, Basterrechea L, Garcia-Alonso M, Gonzalez-Larriba J, Perez-Valderrama B, Cruz-Jurado J, del Alba A, Moreno F, Reynes G, Rodriguez-Remirez M, Boni V, Mahillo-Fernandez I, Martin Y, Viqueira A, Garcia-Foncillas J

Publicada: 24 ene 2017
Resumen:
Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.

Filiaciones:
Cebrian A:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

del Pulgar T:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

Mendez-Vidal M:
 Reina Sofia Univ Hosp, Cordoba, Spain

Gonzalvez M:
 Virgen de la Arrixaca Univ Hosp, Murcia, Spain

Lainez N:
 Complejo Hosp Navarra, Pamplona, Spain

Castellano D:
 12 Octubre Univ Hosp, Madrid, Spain

Garcia-Carbonero I:
 Virgen Salud Univ Hosp, Toledo, Spain

Esteban E:
 Cent Univ Hosp Asturias, Oviedo, Spain

Saez M:
 Virgen de la Victoria Univ Hosp, Malaga, Spain

Villatoro R:
 Hosp Costa del Sol, Marbella, Spain

Suarez C:
 Vall dHebron Univ Hosp, Barcelona, Spain

Carrato A:
 Ramon y Cajal Univ Hosp, Madrid, Spain

Munarriz-Ferrandiz J:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Basterrechea L:
 Hosp Donostia, San Sebastian, Spain

Garcia-Alonso M:
 Insular Gran Canaria Univ Hosp, Islas Canarias, Spain

Gonzalez-Larriba J:
 Clin San Carlos Univ Hosp, Madrid, Spain

Perez-Valderrama B:
 Virgen del Rocio Univ Hosp, Seville, Spain

Cruz-Jurado J:
 Canarias Univ Hosp, Santa Cruz De Tenerife, Islas Canarias, Spain

del Alba A:
 Son Espases Univ Hosp, Palma De Mallorca, Spain

Moreno F:
 Fuenlabrada Univ Hosp, Fuenlabrada, Spain

Reynes G:
 La Fe Univ Hosp, Valencia, Spain

Rodriguez-Remirez M:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

Boni V:
 Ctr Appl Med Res, Pamplona, Spain

Mahillo-Fernandez I:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

Martin Y:
 Trial Form Support, Madrid, Spain

Viqueira A:
 Pfizer Oncol, Madrid, Spain

Garcia-Foncillas J:
 Fdn Jimenez Diaz Univ Hosp, Madrid, Spain
ISSN: 20452322





Scientific Reports
Editorial
NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 7 Número:
Páginas:
WOS Id: 000392482800001
ID de PubMed: 28117391

MÉTRICAS